Skip to main content
. 2017 Apr 12;8(25):41143–41153. doi: 10.18632/oncotarget.17068

Figure 2. AR tumor expression in primary and metastatic lesions of our “Case dataset”.

Figure 2

From Case 1 to Case 10 (A, C: H&E, 10x/B-D: AR, 10x, Case 1; E, G: H&E, 10x/F, H: AR, 10x, Case 2; I, K: H&E, 10x/J, L: AR, 10x, Case 3; M, O: H&E, 10x/N, P: AR, 10x, Case 4; Q, S: H&E, 10x/R, T: AR, 10x, Case 5; U, W: H&E, 10x/V, X: AR, 10x, Case 7; Y, AA: H&E, 10x/Z-, AB: AR, 10x, Case 8; AC, AE: H&E, 10x/AD, AF: AR, 10x, Case 9; AG, AI: H&E, 10x/AH, AJ: AR, 10x, Case 10). Case 6 is not showed as excluded from the immunohistochemical analysis, due to insufficient residual cancer after neoadjuvant chemotherapy.